10d agoInvesting.com Analyst RatingsNEUTRAL 50Analyst
H.C. Wainwright reiterates Alnylam stock rating on TTR guidance cut
H.C. Wainwright reiterates Alnylam stock rating on TTR guidance cut
Archived explainer. For the current picture see today's ALNY page.
Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Down Today?
By the Top Tier Newswire AI Desk · July 31, 2026 at 7:57 AM ET · reviewed against 11 wire stories
ALNYLAM PHARMACEUTIC (ALNY) is down -28.31% in the latest session. Our newswire has captured 11 stories on ALNY across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Alnylam Pharmaceuticals (ALNY) stock fell 28.31% to $205.48 on July 30, 2026, following a guidance cut related to its TTR franchise amid slowing second-line demand for AMVUTTRA. The company reported record TTR net product revenue growth in Q2 2026 but revised its full-year 2026 outlook downward, signaling a shift in market expectations. The stock opened slightly higher at $207.25 but quickly declined throughout the session, reaching a low of $204.02 before settling at $204.48.
What Happened
Alnylam Pharmaceuticals held its Q2 2026 earnings call, during which the company highlighted a first-time TTR franchise revenue exceeding $1 billion. However, it also announced a reduction in full-year guidance, citing the normalization of second-line demand for AMVUTTRA. This adjustment led to immediate downward pressure on the stock. The company also provided a forecast of $4.7B to $5.1B in 2026 product revenue, while maintaining a target of 25% TTR revenue CAGR through 2030. Despite these long-term goals, the near-term guidance cut overshadowed the positive performance, prompting a sharp sell-off.
What The Data Shows
The stock’s intraday session opened with a modest 0.9% gap up from the prior close but quickly reversed course. Volume remained at 0.0M shares, matching the 3-month daily average of 0.0M. The stock’s 52-week range is $197.81 to $495.55, and its current price is near the lower end of that range. Recent insider transactions show one sale totaling $1.1M by a director on June 1, 2026. No other insider transactions or congressional trades have occurred in the past 90 days that directly relate to ALNY.
What To Watch
Alnylam Pharmaceuticals has no upcoming earnings date in the immediate future. Investors should monitor the company’s coverage breadth, as 11 stories from 7 sources have appeared in the last 36 hours. The market will likely assess how the guidance cut aligns with long-term growth targets and whether demand normalization is a temporary or structural shift.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALNY by the numbers
Last: $205.48Session: -28.31%Coverage: 11 stories / 7 sourcesAI sentiment: 54/100 (mixed)Mkt cap: $38.5BP/E: 52.052w: $197.81 to $495.55
The headlines behind the move
10d agoThe Motley FoolBULLISH 73Earnings
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
10d agoTipRanksBULLISH 63Earnings
Alnylam Q2 2026 Earnings Call Shows TTR Strength
Alnylam Pharmaceuticals (($ALNY)) has held its Q2 earnings call. Read on for the main highlights of the call. Alnylam’s latest earnings call struck an optimistic to...
11d agoSeeking AlphaBULLISH 63Earnings
Alnylam forecasts $4.7B-$5.1B in 2026 product revenue while targeting 25% TTR revenue CAGR through 2030
Alnylam (ALNY) Q2 2026 earnings call recap: AMVUTTRA tops $1B, guidance cut on 2nd-line demand, China deal, TRITON-CM update—read now.
11d agoSeeking AlphaNEUTRAL 50Earnings
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDTCompany ParticipantsJosh BrodskyYvonne Greenstreet - CEO &...
11d agoSeeking AlphaNEUTRAL 50Earnings
Alnylam Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-07-30. The following slide deck was published by Alnylam Pharmaceuticals, Inc.
11d agoSeeking AlphaBEARISH 32Earnings
Alnylam drops after guidance cut on ATTR-CM headwinds
Alnylam Pharmaceuticals (ALNY) stock plunges as the company, with its Q2 2026 results, lowers its full-year outlook. Read more here.
11d agoMarketChameleonBULLISH 73Earnings
Alnylam Pharmaceuticals Delivers Record TTR Growth as Strategic Pipeline Advancements Signal Long-Term Value July 30, 2026
Alnylam Pharmaceuticals reported a landmark quarter, driven by robust TTR net product revenue growth and strategic pipeline progress, while updating its guidance to reflect normalized demand trends. The company continues to expand its global reach, advance its clinical programs, and deepen AI collaborations, reinforcing its leadership in RNAi therapeutics.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ALNY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALNY move explainers: 2026-07-31 · 2026-07-30 · 2026-07-20 · 2026-07-17